Clinical trials: Migraine Prophylaxis
Migraine
Probiotics for the Prophylaxis of Migraine
This study aims to understand the efficacy of two probiotic interventions as prophylaxes of migraine symptoms in individuals diagnosed with episodic migraine.
- Trial name
- MIGR_PRO2 (NCT04305522)
- Testing
- Probiotic 1, Probiotic 2
- Where
- 2 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Biopolis S.L.
Migraine Disorders
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- PROMISE 2 (NCT02974153)
- Testing
- ALD403 (Eptinezumab)
- Where
- 144 sites in United States, Belgium and 11 more
- Volunteers
- 1,121 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
- Trial name
- NCT05217927
- Testing
- Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing
- Where
- 107 sites in United States, Austria and 8 more
- Volunteers
- 1,415 people
- Sponsor
- Pfizer
Migraine
An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of migraine headaches in adults. Topiramate has been approved to prevent migraine headaches in adults.
- Trial name
- NCT00210860
- Testing
- topiramate
- Volunteers
- 142 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine
A Randomized, Multicenter, Study for the prEvention and Acute Treatment of Migraine (REAL)
This is a randomized study for the prevention and acute treatment of migraine using open label nVNS and standard of care versus standard of care. .
- Trial name
- REAL (NCT03787238)
- Testing
- non-invasive vagus nerve stimulation
- Where
- 17 sites in Denmark, Germany and 3 more
- Sponsor
- ElectroCore INC
Migraine Disorders
An Observational Study Evaluating the Safety of Topiramate for the Prevention of Migraine
A 6-month, observational, post authorization safety study for the collection and evaluation of additional safety data on topiramate as a prophylactic treatment for migraines in adult patients.
- Trial name
- NCT00297336
- Testing
- Topiramate
- Volunteers
- 80 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Migraine
A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches
The purpose of this study is to assess the safety and effectiveness of topiramate as compared to placebo for the prevention of headaches in patients with chronic migraine.
- Trial name
- NCT00210912
- Testing
- topiramate
- Volunteers
- 328 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Episodic Migraine
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- TANDEM (NCT05264129)
- Testing
- Atogepant, Ubrogepant
- Where
- 37 sites in United States
- Volunteers
- 263 people
- Sponsor
- AbbVie
Migraine
Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Preventative Treatment for Migraine
This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical…
- Trial name
- A-MI-01 (NCT07279623)
- Testing
- INMEST-treatment
- Where
- Sweden
- Volunteers
- 110 people
- Sponsor
- Abilion Medical Systems AB
Chronic Migraine, Episodic Migraine
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).
- Trial name
- JPN ATO OLE (NCT04437433)
- Testing
- Atogepant 60 mg
- Where
- 24 sites in Japan
- Volunteers
- 186 people
- Sponsor
- AbbVie
Intervention
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.
- Trial name
- NCT02991430
- Testing
- active neuromodulation for episodic migraine headache
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Scion NeuroStim
Chronic Migraine
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
- Trial name
- NCT03855137
- Testing
- Atogepant 30 mg, Atogepant 60 mg
- Where
- 150 sites in United States, Australia and 15 more
- Volunteers
- 778 people
- Sponsor
- Allergan
Chronic Migraine, Headache
Open Label, 6-month Study for High Frequency and Chronic Migraine,
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs/month) requiring preventive treatment. Enrolled patients will receive DAX administered subcutaneously using an established, published…
- Trial name
- NCT06133491
- Testing
- Daxibotulinumtonix A
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Ki Health Partners. LLC
Migraine, Episodic Migraine
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Randomized study of two digital therapeutics for the prevention of episodic migraine
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Trial name
- ReMMi-D (NCT05853900)
- Testing
- ReMMi-D Digital Therapeutic
- Where
- United States
- Volunteers
- 568 people
- Sponsor
- Click Therapeutics, Inc.
Episodic Migraine, Chronic Migraine
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
- Trial name
- NCT04686136
- Testing
- Atogepant 60 mg
- Where
- 116 sites in United States, Canada and 12 more
- Volunteers
- 596 people
- Sponsor
- AbbVie
Migraine Headaches
A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine headache relief.
- Trial name
- NCT00109083
- Testing
- RWJ-333369
- Where
- 25 sites in United States
- Volunteers
- 300 people
- Sponsor
- SK Life Science, Inc.
Migraine
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.
- Trial name
- EVOLVE-1 (NCT02614183)
- Testing
- Galcanezumab
- Where
- 95 sites in United States, Canada and 1 more
- Volunteers
- 862 people
- Sponsor
- Eli Lilly and Company
Migraine
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PRACTICE (NCT07690215)
- Volunteers
- 200 people
- Sponsor
- AbbVie
Migraine, Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg…
- Trial name
- NCT04041284
- Testing
- Fremanezumab
- Where
- 64 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
An Open Label Extension of a Study of Topiramate in Chronic Migraine.
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of headaches in adults with chronic migraine. Topiramate has been approved to prevent migraine headaches.
- Trial name
- NCT00210873
- Testing
- topiramate
- Volunteers
- 200 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.